Overall, the results of CVOTs published so far seems to suggest that the gap between the cardiorenal benefits of SGLT-2 and GLP-1RA is narrowing (Cardiovascular Diabetology)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Low glycaemic state increases risk of frailty and functional decline in older people with type 2 diabetes mellitus – evidence from a systematic review
Low glycaemia increases risk of frailty and functional decline in older people with type 2 diabetes. Management should minimise incidence of low glycaemia in these patients (Diabetes Research and Clinical Practice)
Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study
A low eGDR (a measure of insulin resistance) is associated with an increased risk of stroke and death in individuals with T2D. The relative attributed risk was most important for hypertension (Cardiovascular Diabetology)
Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort
In this study, a high HbA1c did not reduce the occurrence of nocturnal hypoglycemia, and low HbA1c was not associated with the highest TIR. Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters (Diabetes Care)
Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study
This study supports the renoprotective benefit of real-world SGLT-2i use irrespective of patient baseline kidney function (Cardiovascular Diabetology)
Effects of SGLT-2 inhibitors on serum uric acid in patients with T2DM: A systematic review and network meta-analysis
SGLT-2 inhibitors could significantly reduce SUA levels in patients with T2DM, especially luseogliflozin (1 mg and 10 mg) and dapagliflozin (5 mg) possess the best effects. Therefore, SGLT-2 inhibitors look extremely promising as an anti-diabetes treatment option in patients with T2DM with high SUA (Diabetes, Obesity and Metabolism)
COncise adVice on Inpatient Diabetes (COVID:Diabetes)
Post COVID-19 diebetes discharge pathway – risk stratification and follow up guidance for people being discharged from secondary care after COVID-19 infection (ABCD)
Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset Type 1 diabetes
GAD-specific immune responses 15 months after lymph node injections of GAD-alum differed from the ones induced by subcutaneous administration of the same autoantigen (Diabetes/Metabolism Research and Reviews)
What Is in the Field for Genetics and Epigenetics of Diabetic Neuropathy: The Role of MicroRNAs
In this scenario, the genetics of microRNAs is at a very preliminary stage. Notwithstanding, the study of genetics and epigenetics of miRNAs may well contribute to the identification of exploratory biomarkers of risk and pathogenetic mechanisms of diabetic neuropathy and to a comprehensive definition of susceptibility to specific pathogenetic mechanisms to favor a tailored mechanism-based treatment or prevention (Journal of Diabetes Research)
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
Pretreatment with empagliflozin protects the heart from subsequent severe lethal ventricular arrhythmia induced by myocardial ischemia and reperfusion injury. These protective benefits may occur as a consequence of activation of the ERK1/2-dependent cell-survival signaling pathway in a glucose-independent manner (Cardiovascular Diabetology)
A Novel Hypothesis Linking Low Grade Ketonemia to Cardio-Renal Benefits with SGLT2-Inhibitors
In this review, we propose a novel hypothesis to link the pleiotropic effects of low grade ketonemia to the cardio-renal benefits seen with the SGLT2-inhibitors (Diabetes, Obesity and Metabolism)
Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study
This study identified multiple prediction models to predict albuminuria, diabetic kidney disease, chronic kidney disease, and end stage renal disease. In the external validation, discrimination and calibration for albuminuria, diabetic kidney disease, and chronic kidney disease varied considerably across prediction horizons and models (BMJ)
All Wales advice on sodium-glucose cotransporter-2 (SGLT-2) inhibitors in type 2 diabetes and cardiovascular disease
This guidance has been developed to help support healthcare professionals in the prescribing of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials
In ADJUNCT ONE and ADJUNCT TWO, the efficacy and glycaemic safety of liraglutide did not depend on subgroups, leaving residual beta-cell function as the only identified variable impacting the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in T1D. These findings support a role for GLP-1 RAs as adjuncts to insulin in T1D, warranting further study (Diabetes, Obesity and Metabolism)
Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: a meta-analysis
This study demonstrated the effectiveness and safety of DPP-4 inhibitors bonded with insulin in patients with T2D and CKD, but the protective actions of this cure on kidney and cardiovascular outcomes, as well as the functions of other DPP-4 inhibitors, need to be affirmed by more good-quality RCTs (Journal of Diabetes Investigation)
Epidemiological Research Advances in Vascular Calcification in Diabetes
Because basic research on the clinical transformation of vascular calcification has yet to be conducted, this study systematically expounds on the risk factors for vascular calcification, vascular bed differences, sex differences, ethnic differences, diagnosis, severity assessments, and treatments to facilitate the identification of a new entry point for basic research and subsequent clinical transformation regarding vascular calcification and corresponding clinical evaluation strategies (Journal of Diabetes Research)
Probing β-Cell Biology in Space and Time
Scientists must be able to investigate (and visualize) short- and long-lived events within the pancreas and β-cells. Current technological advances in microscopy are able to bridge multiple spatiotemporal scales in biology to reveal the complexity and heterogeneity of β-cell biolog (Diabetes)
Randomised Controlled Trials in Diabetes Research: A Pathway to Interpreting Published Results
We have developed a checklist of points we consider most important when reading and interpreting RCT publications (Diabetes Therapy)
Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Use of SGLT2 inhibitors versus GLP-1 RAs was associated with consistent reductions in HHF risk among T2D patients with and without CVD, although the absolute benefit was greater in patients with CVD. There were no large differences in risk for MI or stroke among T2D patients with and without CVD (Annals of Internal Medicine)
Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study
Patients receiving OW semaglutide experienced statistically significant and clinically relevant reductions from baseline in HbA1c and body weight. These results are in line with those of the SUSTAIN RCTs and support the use of OW semaglutide in routine clinical practice in adults with T2D in the UK (Diabetes Therapy)
Glycosmedia is also available as an App: